Physicians' Academy for Cardiovascular Education
In a randomized trial of patient with paroxysmal AF, initial strategy of cryoballoon ablation significantly reduced rate of recurrence of atrial tachyarrhythmia compared to antiarrhythmic drug therapy.
This study in a large community-based cohort showed that even low amounts of alcohol consumption are associated with increased risk of incident AF.
Global CVD burden has increased in almost all regions outside high-income countries. The increase was largely due to population growth and aging. In addition, attribution of risk factors like SBP, BMI, and dietary risk increased worldwide.
AHA 2020 Use of rivaroxaban was as effective as warfarin in reducing the net clinical outcome of all-cause mortality, major CV events or major bleeding in AF patients with a bioprosthetic mitral valve.
AHA 2020 The VITAL-Rhythm trial showed that daily omega-3 fatty acids and/or vitamin D3 supplementation had no effect on the primary prevention of incident AF.
In the GARFIELD-AF registry, most AF patients received recommended doses of NOAC. Those with nonrecommended doses (underdosing or overdosing) had increased risk of mortality compared to those with recommended doses.
ESC 2020 During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes.
ESC 2020 The EAST-AFNET4 trial showed that patients with early AF and CV conditions benefit from early rhythm control therapy compared to patients who received standard therapy.
ESC 2020 Prof. Kirchhof shares the findings of the EAST-AF NET 4 trial, which evaluated the effect of early rhythm control in patients who were recently diagnosed with AF compared to usual care.
This expanded analysis of the CABANA trial showed that catheter ablation reduced symptomatic and asymptomatic AF recurrence and AF burden as compared to drug therapy over a 5-year follow-up period.
This retrospective cohort study used longitudinal data from 4 European health care databases to compare the risk of major bleeding in DOAC and VKA users with nonvalvular atrial fibrillation (NVAF).
This analysis of the REGARDS study showed that AF patients without CV comorbidities had no increased risk of stroke compared to individuals without AF or CV comorbidities.
